Bendamustine/polatuzumab-vedotin/rituximabLack of efficacy following an off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2022年 / 1935卷 / 1期

关键词：

D O I：

10.1007/s40278-022-28908-6

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：113 / 113

相关论文

共 50 条

[1] Bendamustine/Polatuzumab-vedotin/RituximabLack of efficacy
[J]. Reactions Weekly, 2024, 2009 (1) : 113 - 113
[2] RituximabLack of efficacy following off-label use: case report
[J]. Reactions Weekly, 2022, 1905 (1) : 444 - 444
[3] Ibrutinib/polatuzumab-vedotin/rituximabLack of efficacy and toxic epidermal necrolysis: case report
[J]. Reactions Weekly, 2022, 1929 (1) : 332 - 332
[4] RituximabLack of efficacy in off-label use: case report
[J]. Reactions Weekly, 2023, 1946 (1) : 492 - 492
[5] RituximabLack of efficacy and off-label: case report
[J]. Reactions Weekly, 2022, 1932 (1) : 522 - 522
[6] Prednisolone/rituximabLack of efficacy and off-label use: case report
[J]. Reactions Weekly, 2021, 1878 (1) : 445 - 445
[7] Bendamustine/polatuzumab-vedotin/rituximabPeripheral neuropathy and lack of efficacy: 4 case reports
[J]. Reactions Weekly, 2022, 1921 (1) : 64 - 64
[8] Bendamustine/polatuzumab-vedotin/rituximabVarious toxicities: 5 case reports
[J]. Reactions Weekly, 2022, 1889 (1) : 84 - 84
[9] Bendamustine/polatuzumab-vedotin/rituximabVarious toxicities and compassionate use: 7 case reports
[J]. Reactions Weekly, 2022, 1927 (1) : 130 - 130
[10] Apixaban/dexamethasone/rituximabLack of efficacy and off-label use: case report
[J]. Reactions Weekly, 2023, 1938 (1) : 219 - 219

← 1 2 3 4 5 →